Archives
IgA Nephropathy in Kidney Transplantation
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
IgA Nephropathy in Kidney Transplantation
Background
IgAN is the most common glomerulonephritis worldwide.1 End-Stage Kidney Disease in IgAN occurs in 15-20% of patients after 10 years and in 20-40% of patients at 20 years.2 Kidney transplant most effective therapy for patients with IgAN, but IgAN can recur in transplanted kidney.2
Did You Know?
Recurrent glomerulonephritis (GN) is the frequent cause of allograft failure at 10 years.2
Why Attend This Webinar?
IgAN is the most common glomerulonephritis worldwide and kidney transplantation offers a solution after end-stage kidney disease.1,3 However, IgAN can recur after kidney transplantation and optimal management is currently unknown.1,4 Join us to hear from Dr. Fahad Aziz, Associate Profession of Nephrology, and Transplant Nephrologist at the University of Wisconsin, Madison, to learn more about IgAN in kidney transplantation!
What You Will Learn:
- Review background of IgA Nephropathy (IgAN)
- Understand recurrence of IgAN after kidney transplantation
- Identify risk factors for IgAN recurrence after kidney transplantation
- Illustrate various resources available to patients
References:
- Guttierez E, et al. Nephron 2020
- Kawabe,M, Yamamoto, I. Current Status and Perspectives on Recurrent IgA Nephropathy after Kidney Transplantation. Nephron 2023;147(suppl 1):9–13
- https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777
- Aziz, F, et al. Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors. Transplantation Reviews 35 2021
Speaker
Fahad Aziz, MD
As a clinical nephrologist, Dr. Aziz cares for people living with a wide range of kidney diseases and disorders including renal transplant recipients. In addition to certification in the practice of internal medicine and nephrology, he holds Hypertension Specialist Certification from the American Society of Hypertension. Dr. Aziz is a member of the American College of Physicians, the American Society of Nephrology (ASN), and the American Society of Transplantation (AST). During his residency training, he was awarded “Best Resident of the Year” on two occasions. He has presented clinical research at national medical conferences at ASN and AST professional society scientific meetings. As a medical educator, he has provided classroom instruction topics in nephrology to physician assistant students and nephrology fellows as well as continuing medical education presentations to clinicians.
Moderators
Jaimini Patel, PharmD, BCCCP
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Jaimini Patel, PharmD, BCCCP, is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Patel earned her Doctorate in Pharmacy from the University of Michigan, Ann Arbor and completed two years of post-doctoral residency at Beaumont Hospital, Royal Oak and Loyola University Medical Center, respectively, specializing in critical care pharmacy practice. Prior to joining Otsuka, Dr Patel practiced as a critical care pharmacist at the Cleveland Clinic Akron General Medical Center for 3.5 years and has cared for patients in the medical, surgical/trauma, cardiothoracic and neuroscience ICUs, and was significantly involved in the care of patients with COVID-19. Dr Patel holds board certification in critical care pharmacotherapy and is a licensed pharmacist in Michigan, Illinois and Ohio. She is also an active member of the Society of Critical Care Medicine through which she is engaged in research and leadership.
Michael Filsinger, MPA, PA-C
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Michael Filsinger, MPA, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh, PA. Following his graduate training, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington, DC Prior to joining Otsuka, Michael spent the last 15 years working in solid organ transplant in Charlotte, NC where he developed a passion for improving the care of patients with renal disease and ESKD.
Dr. Fahad Aziz, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Jaimini Patel, PharmD, BCCCP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Michael Filsinger, MPA, PA-C is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
